Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

IMMP – Immutep Limited ADR

Float Short %

3.17

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

EPS Last/This Y

0.02

EPS This/Next Y

0.02

Price

2.79

Target Price

8.77

Analyst Recom

1.38

Performance Q

59.43

Upside

-225.8%

Beta

1.76

Ticker: IMMP




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23IMMP3.170.270.063082
2026-01-26IMMP3.180.260.323180
2026-01-27IMMP3.090.260.323180
2026-01-28IMMP3.070.270.073249
2026-01-29IMMP2.980.260.003330
2026-01-30IMMP2.730.260.333333
2026-02-02IMMP2.870.380.133674
2026-02-03IMMP2.830.385.173675
2026-02-04IMMP2.690.3710.953668
2026-02-05IMMP2.640.426.673804
2026-02-06IMMP2.630.420.503811
2026-02-09IMMP2.730.440.003994
2026-02-10IMMP2.80.440.384003
2026-02-11IMMP2.790.443.334021
2026-02-12IMMP2.730.440.004036
2026-02-13IMMP2.650.430.034065
2026-02-17IMMP2.760.430.004098
2026-02-18IMMP2.80.420.204123
2026-02-20IMMP2.780.410.304421
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23IMMP3.16- -88.1-0.25
2026-01-26IMMP3.17- -80.0-0.25
2026-01-27IMMP3.10- -77.1-0.25
2026-01-28IMMP3.06- -75.0-0.25
2026-01-29IMMP2.98- -71.5-0.25
2026-01-30IMMP2.73- -65.9-0.25
2026-02-02IMMP2.87- -73.3-0.25
2026-02-03IMMP2.83- -72.2-0.25
2026-02-04IMMP2.69- -65.2-0.25
2026-02-05IMMP2.62- -61.4-0.25
2026-02-06IMMP2.63- -64.6-0.25
2026-02-09IMMP2.75- -67.6-0.26
2026-02-10IMMP2.80- -63.5-0.26
2026-02-11IMMP2.78- -60.3-0.26
2026-02-12IMMP2.73- -58.6-0.26
2026-02-13IMMP2.64- -54.1-0.26
2026-02-17IMMP2.75- -64.3-0.26
2026-02-18IMMP2.80- -66.8-0.26
2026-02-19IMMP2.86- -69.9-0.26
2026-02-20IMMP2.79- -66.4-0.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23IMMP0.005.473.35
2026-01-26IMMP0.005.093.35
2026-01-27IMMP0.005.093.35
2026-01-28IMMP0.005.093.25
2026-01-29IMMP0.005.093.25
2026-01-30IMMP0.005.093.25
2026-02-02IMMP0.005.063.25
2026-02-03IMMP0.005.063.25
2026-02-04IMMP0.005.063.25
2026-02-05IMMP0.005.063.25
2026-02-06IMMP0.005.063.25
2026-02-10IMMP0.0059.233.25
2026-02-11IMMP0.0059.233.17
2026-02-12IMMP0.0059.233.17
2026-02-13IMMP0.0059.233.17
2026-02-17IMMP0.0011.963.17
2026-02-18IMMP0.0011.963.17
2026-02-19IMMP0.0011.963.17
2026-02-20IMMP0.0011.963.17
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

11.96

Beta

1.76

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

15

Growth Score

18

Sentiment Score

72

Actual DrawDown %

48.7

Max Drawdown 5-Year %

-72.9

Target Price

8.77

P/E

Forward P/E

PEG

P/S

P/B

4.33

P/Free Cash Flow

EPS

-0.27

Average EPS Est. Cur. Y​

-0.26

EPS Next Y. (Est.)

-0.24

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.09

Return on Equity vs Sector %

-71.8

Return on Equity vs Industry %

-54.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

-66.4
Immutep Limited
Sector: Healthcare
Industry: Biotechnology
Employees:
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
stock quote shares IMMP – Immutep Limited ADR Stock Price stock today
news today IMMP – Immutep Limited ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMMP – Immutep Limited ADR yahoo finance google finance
stock history IMMP – Immutep Limited ADR invest stock market
stock prices IMMP premarket after hours
ticker IMMP fair value insiders trading